CA1306694C - Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida) - Google Patents
Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida)Info
- Publication number
- CA1306694C CA1306694C CA000573644A CA573644A CA1306694C CA 1306694 C CA1306694 C CA 1306694C CA 000573644 A CA000573644 A CA 000573644A CA 573644 A CA573644 A CA 573644A CA 1306694 C CA1306694 C CA 1306694C
- Authority
- CA
- Canada
- Prior art keywords
- dextran sulfate
- pharmaceutical preparation
- htlv
- hydrogenated dextran
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000010076 replication Effects 0.000 title claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 12
- 230000002401 inhibitory effect Effects 0.000 title claims description 7
- 241000700605 Viruses Species 0.000 title abstract description 13
- 238000000034 method Methods 0.000 title description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- -1 dextran sulphate derivative Chemical class 0.000 claims abstract description 5
- 230000001066 destructive effect Effects 0.000 claims abstract 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract 2
- 229960000633 dextran sulfate Drugs 0.000 claims description 36
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000005083 Zinc sulfide Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052984 zinc sulfide Inorganic materials 0.000 claims 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 abstract description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract description 15
- 229910021653 sulphate ion Inorganic materials 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000014508 negative regulation of coagulation Effects 0.000 abstract description 4
- 239000005864 Sulphur Substances 0.000 abstract description 3
- 230000019635 sulfation Effects 0.000 abstract description 3
- 238000005670 sulfation reaction Methods 0.000 abstract description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 abstract description 2
- 230000000740 bleeding effect Effects 0.000 abstract description 2
- 238000005984 hydrogenation reaction Methods 0.000 abstract description 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229960002086 dextran Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003463 sulfur Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 241000428533 Rhis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229920001448 anionic polyelectrolyte Polymers 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000006448 coagulant property Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- WRSZRYQLLVUDNG-UHFFFAOYSA-N formamide;sulfurochloridic acid Chemical compound NC=O.OS(Cl)(=O)=O WRSZRYQLLVUDNG-UHFFFAOYSA-N 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000573644A CA1306694C (fr) | 1988-08-02 | 1988-08-02 | Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida) |
| ZA891535A ZA891535B (en) | 1988-08-02 | 1989-02-28 | Dextran sulphate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000573644A CA1306694C (fr) | 1988-08-02 | 1988-08-02 | Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1306694C true CA1306694C (fr) | 1992-08-25 |
Family
ID=4138477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000573644A Expired - Lifetime CA1306694C (fr) | 1988-08-02 | 1988-08-02 | Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida) |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA1306694C (fr) |
| ZA (1) | ZA891535B (fr) |
-
1988
- 1988-08-02 CA CA000573644A patent/CA1306694C/fr not_active Expired - Lifetime
-
1989
- 1989-02-28 ZA ZA891535A patent/ZA891535B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA891535B (en) | 1989-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
| Harakeh et al. | Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. | |
| Nakashima et al. | Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro | |
| Ito et al. | Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)] | |
| Soudeyns et al. | Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog | |
| DE3650377T2 (de) | Regulierung der retroviralen replikation, infektion und pathogenese. | |
| AT401470B (de) | Pharmazeutische verwendung von 17-ketosteroiden | |
| Gram et al. | Valproate sodium: a controlled clinical trial including monitoring of drug levels | |
| DE3886710T2 (de) | Verfahren zur selektiven inhibierung von hiv. | |
| US5246970A (en) | Method of inhibiting nitric oxide formation | |
| TURANO et al. | Inhibitory effect of papaverine on HIV replication in vitro | |
| AU640511B2 (en) | Hexa-n-(o-hydroxybenzyl) neomycin b for inhibiting human retroviruses and for the treatment of aids | |
| DE68914990T2 (de) | Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo. | |
| US5026726A (en) | Gossylic iminolactones and gossylic lactones and their anti-viral activities | |
| KR20000069296A (ko) | 항바이러스 활성을 갖는 살비아 종의 추출물 | |
| DE60118592T2 (de) | Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus | |
| US5057325A (en) | Method of inhibiting replication of HIV with water-soluble melanins | |
| CA1306694C (fr) | Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida) | |
| EP0183352A2 (fr) | Utilisation de suramine pour clinothérapie des infections par quelques-uns des membres de la famille des virus humains leucémiques de cellules-T (HTLV) y compris le virus lymphadénopathique (LAV) | |
| JPH05504774A (ja) | エイズ治療を増進するためのメタロポルフィリン類の使用 | |
| DE19813802A1 (de) | Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen | |
| Ruprecht et al. | Castanospermine vs. its 6-O-butanoyl analog: a comparison of toxicity and antiviral activity in vitro and in vivo | |
| EP0255420B1 (fr) | Agent antiviral d'inhibition de la croissance du virus du syndrome immuno-deficitaire acquis (SIDA) | |
| Anand et al. | Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro | |
| EP0295962B1 (fr) | Polysaccharide protéinique pour le traitement des infections réovirales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |